Alecensa – Talk Bio

Actionable Insights Powered by AI

Roche’s Alecensa Gains FDA Approval for Postsurgical Early Lung Cancer Treatment

1 year ago talkbio0Tagged Alecensa, Approved, Malignant neoplasm of lung, Postsurgical, Roche (company), United States Food and Drug Administration

Roche, Alecensa, FDA approval, Postsurgical treatment, Early lung cancer

Alecensa: FDA-Approved First ALK Inhibitor for Adjuvant Treatment in Early-Stage ALK-Positive NSCLC

1 year ago talkbio0Tagged Alecensa, ALINA, ALK gene, ALK Positive, Approved, Cessation of life, disease recurrence, Early-stage, genentech, Guidelines, Immunologic Adjuvants, Inhibitor, NCCN, Non-Small Cell Lung Carcinoma, Roche (company), United States Food and Drug Administration

Alecensa, ALK Inhibitor, Adjuvant Treatment, Early-Stage ALK-Positive NSCLC, FDA Approval, Genentech, Roche Group, ALINA Study, 76% Reduction in Disease Recurrence or Death, NCCN Guidelines